Stories of healthcare workers on the front lines of the global tuberculosis epidemic
Advancing New TB Vaccines for the World
New on the Blog
Aeras hosted the 2015 Fall meeting of the Biomarkers and Correlates Working Group (BCWG) to discuss and make recommendations for the TB vaccine community.
2014 Annual Report
New trials, new partnerships and new milestones made 2014 an exciting year for TB vaccine development at Aeras.
Progress in the Pipeline
Together with our partners, we've made significant advances over the past decade using diverse and innovative strategies.
Collaboration for Innovation.
View this slideshow and see how we can change the lives of more than 8.6 million people.
TB is more complex than ever.
TB is becoming more complex and difficult to treat. The rise in multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains is making the disease harder and exponentially more expensive to fight and presents a threat to health in every country.
We are a nonprofit biotech advancing TB vaccines.
With a focus on innovation and impact, Aeras works with leading partners around the world to develop new TB vaccines that will be affordable and accessible to all who need them.
Vaccines are the most cost-effective approach.
TB will not be eliminated without successful new vaccines for both adults and children.
We collaborate within a vast network.
Aeras serves as a catalyst by investing in the world’s most promising TB vaccine candidates and collaborating to strengthen and advance the global pipeline.